Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC with gemcitabine for pancreatic carcinomatosis
2016-004298-41Phase 2Active
- Sponsor
- Hospital General Universitario Ciudad Real
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine in pancreatic adenocarcinoma (PDAC) and pancreatic cancer with peritoneal metastasis (2 arms), sponsored by Hospital General Universitario Ciudad Real. Primary endpoints: Overall survival and Treatment-related morbidity and mortality. Started Mar 2017; status: active.
02
Drugs
gemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer with peritoneal metastasis
Beyond the preview
Go deeper on 2016-004298-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004298-41.